Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer Therapies.

Autor:	Kowalski A; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Lykon J; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Diamond B; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Coffey DG; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Kaddoura M; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Maura F; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Hoffman JE; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Kazandjian D; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida., Landgren O; Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Jazyk:	angličtina
Zdroj:	Blood cancer discovery [Blood Cancer Discov] 2024 Mar 01; Vol. 5 (2), pp. 90-94.
DOI:	10.1158/2643-3230.BCD-23-0228
Abstrakt:	Summary: Immune-related toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common side effects of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapies of hematologic malignancies. As anti-inflammatory therapy (the standard of care) is variably effective in mitigating these toxicities after onset, here we discuss emerging evidence for shifting the strategy from mitigation to prevention. (©2024 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu